logo
logo

Invetx Announces Completion of $25.5 Million Series A Financing and Key Appointments to Executive Team

Invetx Announces Completion of $25.5 Million Series A Financing and Key Appointments to Executive Team

09/30/20, 12:43 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgboston
Money raised
$25 million
Round Type
series a
Invetx, a pioneer in protein-based therapeutics for animal health, announced today that it has raised an additional $10.25 million in its Series A financing, bringing the total amount to $25.5 million. New investors include Casdin Capital and funds managed by Tekla Capital Management, LLC, joining existing lead investor Anterra Capital, as well as strategic investors AbCellera Biologics and WuXi Biologics. In addition, Invetx announced the appointments of Bill Brondyk, PhD, as chief scientific officer and Colin Giles, PhD, as chief development officer to its executive team.

Company Info

Company
Invetx
Location
boston, massachusetts, united states
Additional Info
Our team of R&D leaders from human biotech and animal health is building the premier biotechnology platform for protein-based therapeutics in animal health.

Related People